Neon Therapeutics Taps Novartis Oncology Exec O’Dowd As CEO

Xconomy Boston — 

Hugh O’Dowd has been named CEO of Cambridge, MA-based immuno-oncology startup Neon Therapeutics, replacing interim CEO and Third Rock Ventures partner Cary Pfeffer. O’Dowd is joining Neon after a more than 20-year stint at Novartis, where he helped commercialize many of the Swiss pharma giant’s cancer drugs, among them imatinib (Gleevec).